IMUX

Immunic Inc

• TipRanks·1d ago

  Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Nurix Therapeutics (NRIX) and Immunic (IMUX)

• PUBT·06/01 21:56

  Immunic files Form 3 initial beneficial ownership statement for CEO Erik Lundgren

• PUBT·06/01 11:22

  Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

• TipRanks·05/29 03:06

  Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

• TipRanks·05/28 11:48

  Immunic Highlights Positive Phase 2 CALLIPER MS Data

• Benzinga·05/28 10:35

  Immunic Announces Presentation Of One Late-Breaking And Two Additional Posters Highlighting Additional Data From Its Phase 2 CALLIPER Trial

• PUBT·05/28 10:32

  Immunic presents new Phase 2 CALLIPER analyses of vidofludimus calcium in progressive multiple sclerosis at CMSC 2026

• Reuters·05/28 10:30

  EQS-NEWS: IMMUNIC TO PRESENT ADDITIONAL PHASE 2 CALLIPER TRIAL DATA FOR VIDOFLUDIMUS CALCIUM AT THE CMSC ANNUAL MEETING 2026, REINFORCING ITS POTENTIAL IN PROGRESSIVE MULTIPLE SCLEROSIS

• TipRanks·05/27 11:37

  Immunic Appoints New CEO to Lead MS Strategy

• NASDAQ·05/27 10:51

  Immunic Names Erik Lundgren Chief Executive Officer

• TipRanks·05/27 10:45

  Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed

• Seeking Alpha·05/27 10:44

  Immunic names Erik Lundgren as CEO; Daniel Vitt steps down

• Dow Jones·05/27 10:32

  *Immunic: Lundgren Succeeds Daniel Vitt, Who Will Retain Responsibility for Scientific Strategy and Portfolio Advancement >IMUX

• PUBT·05/27 10:30

  Immunic names ex-Genentech executive Erik Lundgren CEO, replacing Daniel Vitt

• Dow Jones·05/27 10:30

  *Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren As Chief Executive Officer >IMUX